RECURRENT MULTIPLE MYELOMA
Clinical trials for RECURRENT MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control OngoingThis study tests a new combination of drugs for people with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see if the combination can shrink or control the cancer. About 39 adults will take part, receiving ei…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 05:02 UTC
-
New 4-Drug cocktail shows promise for Tough-to-Treat myeloma
Disease control OngoingThis study tests a combination of four drugs (isatuximab, carfilzomib, pomalidomide, and dexamethasone) in 30 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see how many patients' tumors shrink or disappear. This is not a cure…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 04:59 UTC
-
New pill aims to boost myeloma treatment – early trial launched
Disease control TerminatedThis early-phase study was designed to test the safety and best dose of an experimental oral drug called GB1211 (selvigaltin) when added to standard therapy for multiple myeloma that has returned or stopped responding. The drug targets a protein linked to inflammation and cancer …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Supercharged immune cells take on Hard-to-Treat myeloma
Disease control OngoingThis early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to prior therapies. It combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and standard chemotherapy. The main goal is to…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Elvira Umyarova • Aim: Disease control
Last updated May 20, 2026 12:08 UTC
-
New hope for Hard-to-Treat myeloma: drug combo targets resistant cancer
Disease control OngoingThis early-phase trial tests a combination of three drugs (elotuzumab, mezigdomide, and dexamethasone) in 12 adults with multiple myeloma that has come back or stopped responding after prior treatments. The goal is to find a safe dose and see if the combination can control the ca…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Abdullah Khan • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC
-
Lab tests aim to match myeloma patients with best drugs
Knowledge-focused OngoingThis pilot study explores whether using a lab test that screens many drugs at once, combined with genetic information, can help choose personalized treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to therapy. The goal is …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 20, 2026 11:53 UTC